Home » Genentech Settles Rituxan Case for $20 Million
Genentech Settles Rituxan Case for $20 Million
Genentech has agreed to pony up $20 million to the U.S. government to settle a qui tam suit alleging kickbacks for off-label promotion of its cancer drug Rituxan.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May